Bredin Investment LLC bought a new position in shares of Bristol-Myers Squibb Co (NYSE:BMY) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 31,586 shares of the biopharmaceutical company’s stock, valued at approximately $1,937,000. Bristol-Myers Squibb makes up 1.6% of Bredin Investment LLC’s holdings, making the stock its 14th largest position.

Several other institutional investors and hedge funds have also modified their holdings of the company. Blue Chip Partners Inc. grew its stake in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 15 shares in the last quarter. Jackson Grant Investment Advisers Inc. grew its stake in shares of Bristol-Myers Squibb by 0.4% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 15 shares in the last quarter. Chilton Investment Co. LLC grew its stake in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock valued at $294,000 after buying an additional 26 shares in the last quarter. Keel Point LLC grew its stake in shares of Bristol-Myers Squibb by 0.6% in the second quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock valued at $352,000 after buying an additional 39 shares in the last quarter. Finally, Hudock Capital Group LLC grew its stake in shares of Bristol-Myers Squibb by 0.4% in the second quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock valued at $656,000 after buying an additional 49 shares in the last quarter. 69.82% of the stock is owned by institutional investors.

Get Bristol-Myers Squibb alerts:

Bristol-Myers Squibb Co (NYSE:BMY) opened at $67.35 on Wednesday. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb Co has a 52-week low of $51.56 and a 52-week high of $70.05. The company has a market cap of $110,230.00, a price-to-earnings ratio of 28.54, a price-to-earnings-growth ratio of 2.14 and a beta of 1.08.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The firm had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same period in the previous year, the business posted $0.63 earnings per share. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. equities analysts predict that Bristol-Myers Squibb Co will post 3.21 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 2.38%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is 67.80%.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of Bristol-Myers Squibb stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the completion of the transaction, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the transaction, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at $585,033.24. The disclosure for this sale can be found here. Insiders own 0.23% of the company’s stock.

Several research firms recently weighed in on BMY. Piper Jaffray Companies reissued a “hold” rating and issued a $60.00 target price on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Vetr raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 target price for the company in a research note on Thursday, February 1st. Leerink Swann raised their target price on shares of Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research note on Tuesday, February 6th. BMO Capital Markets decreased their target price on shares of Bristol-Myers Squibb from $52.00 to $51.00 and set an “underperform” rating for the company in a research note on Tuesday, February 6th. Finally, Citigroup set a $78.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday, February 16th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $66.73.

WARNING: “31,586 Shares in Bristol-Myers Squibb Co (BMY) Acquired by Bredin Investment LLC” was published by BBNS and is the property of of BBNS. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://baseballnewssource.com/markets/31586-shares-in-bristol-myers-squibb-co-bmy-acquired-by-bredin-investment-llc/1898196.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).